195 related articles for article (PubMed ID: 27546072)
1. Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S; Sutiman N; Zhang CZ; Yu Y; Lam S; Khor CC; Chowbay B
Drug Metab Rev; 2016 Nov; 48(4):502-540. PubMed ID: 27546072
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
[TBL] [Abstract][Full Text] [Related]
3. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
de Jong FA; Marsh S; Mathijssen RH; King C; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2004 Sep; 10(17):5889-94. PubMed ID: 15355921
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
[TBL] [Abstract][Full Text] [Related]
6. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
7. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Hor SY; Lee SC; Wong CI; Lim YW; Lim RC; Wang LZ; Fan L; Guo JY; Lee HS; Goh BC; Tan T
Pharmacogenomics J; 2008 Apr; 8(2):139-46. PubMed ID: 17876342
[TBL] [Abstract][Full Text] [Related]
8. [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].
Sai K; Sawada J; Minami H
Yakugaku Zasshi; 2008 Apr; 128(4):575-84. PubMed ID: 18379174
[TBL] [Abstract][Full Text] [Related]
9. The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Durmus S; van Hoppe S; Schinkel AH
Drug Resist Updat; 2016 Jul; 27():72-88. PubMed ID: 27449599
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Lal S; Mahajan A; Chen WN; Chowbay B
Curr Drug Metab; 2010 Jan; 11(1):115-28. PubMed ID: 20302569
[TBL] [Abstract][Full Text] [Related]
11. Role of pharmacogenetics in irinotecan therapy.
de Jong FA; de Jonge MJ; Verweij J; Mathijssen RH
Cancer Lett; 2006 Mar; 234(1):90-106. PubMed ID: 16343744
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S; Sutiman N; Ooi LL; Wong ZW; Wong NS; Ang PCS; Chowbay B
Pharmacogenomics J; 2017 Jul; 17(4):337-343. PubMed ID: 26975227
[TBL] [Abstract][Full Text] [Related]
13. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
15. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
O'Malley M; King AN; Conte M; Ellingrod VL; Ramnath N
J Thorac Oncol; 2014 Jul; 9(7):917-926. PubMed ID: 24926542
[TBL] [Abstract][Full Text] [Related]
16. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Lim J; Singh O; Chen X; Tan EH; Lee EJ; Chowbay B
Eur J Clin Pharmacol; 2014 Feb; 70(2):155-66. PubMed ID: 24193570
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
20. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
